Clinical Trials Directory

Trials / Unknown

UnknownNCT05830019

Carbon Ion Radiotherapy for Recurrent Pancreatic Cancer Post Surgery

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
49 (estimated)
Sponsor
Shanghai Proton and Heavy Ion Center · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to evaluate the toxicity and tolerance of carbon ion radiotherapy for recurrent pancreatic carcinoma post surgery

Detailed description

The carbon dose of 67.5 Gy equivalent in 15 fractions was delivered to clinical target volume (CTV). The dose limiting toxicity (DLT) was defined as CTCAE grade 3 or higher of non-hematological toxicity (G3). The acute and late toxicities, overall survival (OS), progression-free survival (PFS), local progression-free survival (LPFS) and distant metastasis-free survival (DMFS) were the endpoints.

Conditions

Interventions

TypeNameDescription
RADIATIONcarbon ion radiotherapycarbon ion radiotherapy

Timeline

Start date
2021-06-01
Primary completion
2024-12-31
Completion
2024-12-31
First posted
2023-04-26
Last updated
2023-04-26

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05830019. Inclusion in this directory is not an endorsement.

Carbon Ion Radiotherapy for Recurrent Pancreatic Cancer Post Surgery (NCT05830019) · Clinical Trials Directory